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• Primary objective: To assess the appropriateness of tirofiban 
utilizing the 2014 AHA/ACC guideline recommendations.   
• Secondary objectives:  
 To identify the indication for tirofiban use 
 Duration of infusion post-PCI  
 Other antiplatelet used in conjunction  
 Assess complications such as bleeding or thrombocytopenia.  
 
 
 
 
 
 
 
• Based on these results, standardization of tirofiban infusion 
protocol  will help with consistency in current practice.  
• FABOLUS PRO trial has shown that tirofiban given as bolus only or 
bolus followed by 2-hour infusion along with clopidogrel or 
prasugrel leads to higher degree of platelet inhibition and obviates 
the need of longer infusion in patients with STEMI.  
• Studies  further investigating similar strategies can help 
standardize use and infusion duration to improve cost-
effectiveness without compromising quality of care. 
 
 
 
  
 
    
*Antiplatelet agents are given with Aspirin 325 mg 
*All tirofiban doses are renally adjusted and given along with tirofiban bolus dose  
 
• Data was collected through retrospective chart review utilizing 
computerized physician order entry (CPOE) and medical records. 
• Patients were randomly selected from period of January 2015 to 
July 2015 who received tirofiban infusion. 
• Data collection included significant medical history, indication for 
tirofiban use, laboratory values (troponin, platelets, renal 
function), tirofiban infusion duration, anti-platelets  used 
concurrently and complications (i.e. bleeding and 
thrombocytopenia) post tirofiban infusion. 
 
 
• Tirofiban is a tyrosine-derived non-peptide Glycoprotein IIb/IIIa 
(GP2b3a) inhibitor . 
• GP2b3a inhibitor therapy during primary percutaneous coronary 
intervention (PCI) decreases the incidence of major adverse 
events as it directly affects the level of platelet inhibition.  
• Currently tirofiban is approved for high-dose IV bolus (HDB) 
regimen of 25mcg/kg within 5 minutes and then 0.15mcg/kg/min 
infusion for up to 18 hours in patients with Non-ST-Elevation 
Myocardial Infarction(NSTEMI) and Unstable Angina(UA) 
undergoing Percutaneous Intervention(PCI). 
• A total of 6 patients (17.1%) were UA, 16 (45.7%) were NSTEMI, 
and 13 (37.2%) were STEMI.  
• All patients (N=35) were loaded with dual anti-platelet agents 
when given tirofiban infusion. 
• Each  tirofiban infusion was given with HDB regimen and was 
renally adjusted when appropriate. 
• All patients had appropriate indications for tirofiban use, but the 
duration of use varied.  
• A total of 3 patients (8.6%) received infusion longer than 18 hours 
and 14 (40%) patients received ≥ 11 hours of tirofiban infusion.  
• All patients who received > 18 hours infusion were not candidates 
of coronary artery bypass grafting.  
• There was no evidence of thrombocytopenia (i.e. 50% drop in 
platelets than baseline or platelets < 100,000/mm3) or  bleeding 
(i.e. signs of bleeding or administration of reversal agent) 
complications post tirofiban infusion.  
 
 
Demographics 
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Figure 1. Comparison of Tirofiban infusion duration on different anti-platelet agents     
Figure 3.  Comparison of Measured Troponin-T and Duration of Tirofiban Infusion 
Figure 2. Comparison of Tirofiban use Indications    
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